科研之友
微信
新浪微博
Facebook
分享链接
摘要
Recently published studies evaluating the efficacy of aliskiren, the first direct renin inhibitor available to treat hypertension, have focused on the effects of this drug on office diastolic blood pressure (DBP), when given either as monotherapy or in association with other anti hypertensive drugs. Safety and tolerability were analyzed using standard parameters. The effects on systolic blood pressure (SBP) and on blood pressure (BP) control rates have been addressed as secondary objectives. This article provides a short review of the efficacy and safety of aliskiren reported in clinical trials. The studies were performed in patients with mild-to-moderate essential hypertension treated with different doses (from 75 to 600 mg a day) of aliskiren given once daily as monotherapy and comparisons were made with placebo or other anti hypertensive drugs. Studies of the short- and long-term effects of combining aliskiren with hydrochlorothiazide, ramipril or amlodipine are also described. As a consequence of its mechanism of direct renin inhibition, aliskiren markedly reduces BP throughout the 24-hour period, in both monotherapy and combination therapy. The magnitude of the BP reduction is similar to that observed with other anti hypertensive drugs when used at equipotent doses. Drug tolerability is similar to that of placebo. The combination of aliskiren with other antihypertensive drugs enhances their efficacy without increasing adverse effects and can even reduce cough induced by angiotensin-converting enzyme (ACE) inhibitors and ankle edema induced by calcium channel blockers. The potential therapeutic role of aliskiren, as an alternative to monotherapy with other antihypertensives or given in combination with them, opens a new chapter in the treatment and control of hypertension as well as in the more effective protection of vital organs.
- 出版日期2009
- 单位河北医科大学
